Outcome of Board Meeting

August 13, 2026 BSE Limited The Manager, Listing Department Corporate Relationship Department, The National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO BSE Scrip Code: 531349 Sub: (1) Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Review Report for the quarter ended June 30, 2026 (2) (i) Date, time & venue of 42nd AGM - Tuesday, September 29, 2026 at 11:30 A.M.; (ii) Appointment of Scrutinizer for e-Voting process at AGM; and (ii) Dates of Book Closure – September 25 – 29, 2026 Ref: Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, In continuation to our letter dated August 08, 2026, and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we would like to inform you that: 1. The Board of Directors has at its meeting held today, i.e. August 13, 2026, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter ended June 30, 2026. The same was also reviewed by the Audit Committee in its meeting held on August 13, 2026. A copy of the said results along with the Limited Review Report is enclosed as Annexure - A. Pursuant to Regulation 46(2)(l) of the SEBI LODR Regulations, the aforesaid statements of financial results are being uploaded on the website of the Company i.e. www.panaceabiotec.com. Further, pursuant to Regulation 47(1)(b) of the SEBI LODR Regulations, the Quick Response Code along with the details of the webpage where complete financial results of the Company for the quarter ended June 30, 2026, are accessible to the Investors, is being sent for publication in newspapers. 2. The Board of Directors has also decided / approved: i) that the 42nd Annual General Meeting of the Members of the Company will be held on Tuesday, September 29, 2026, at 11:30 A.M. through Video Conferencing / Other Audio-Visual Means and approved draft Notice convening Annual General Meeting; Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: companysec@panaceabiotec.com ii) that the Register of Members and Share Transfer Books will remain closed from Friday, September 25, 2026, to Tuesday, September 29, 2026 (both days inclusive) for the purpose of Annual General Meeting; and iii) the appointment of Mr. Debabrata Deb Nath, Partner of R&D Company Secretaries, to act as Scrutinizer for e-Voting process on behalf of the Company for the purpose of ensuing Annual General Meeting. The meeting of the Board of Directors commenced at 04:46 P.M. and concluded at 05:27 P.M. This is for your information and records please. Thanking you Sincerely yours, for Panacea Biotec Limited Ankit Jain General Manager - Legal and Company Secretary Encl. As Above Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: companysec@panaceabiotec.com ~ Extract of Standalone and Consolidated Financial Results (Unaudited) Panacea Biotec for the Quarter ended June 30, 2026 ln1l':,v,1t•on in S.UPI.H.>rt of ur, (f in Lakh except per share) Standalone Consolidated Quarter ended Year ended Quarter ended Year ended March 31, June 30, March 31, June 30, March 31, June JO, March 31, Particulars June JO, 2026 2026 2025 2026 2026 2026 2025 2026 (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Refer note 4) (Refer note 4) Total income from operations 13,471 11,112 11,225 41,349 19,957 16,675 16,670 63,977 Net Profit I (Loss) for the period/year (before tax, exceptional and/or extraordinary item) 200 (461) (884) (4,385) 83 (396) (476) (2,687) Net Profit/ (Loss) for the period/year before tax (after exceptional and/or extraordinary item) 200 (461) (884) (4,385) 357 (125) 656 (737) Net Profit/ (Loss) for the period/year after tax (after exceptional and/or extraordinary item) 139 (18) (670) (2,988) 220 (100) 396 (716) Total comprehensive income/ (loss) for the period/ year (comprising of profit/ (loss) for the 167 59 (668) (2,874) 258 399 394 (I 74) period / year (after tax) and other comprehensive income (after tax)) Equity Share Capital (face value oft I per share) 613 613 613 613 613 613 613 613 Earning/ (loss) per equity share, (annualised, except for quarters): Basic and Diluted (in t) 0.23 (0.03) (1.09) (4.88) 0.38 0.08 0.66 (0.88) Noles: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchanges websites, NSE- https://www.nseindia.com, BSE- https://www.bseindia.com and is also available on the Company's website, https://www.panaceabiotec.com. 2 The financial results for the Quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2026, and have been reviewed by the statutory auditor of the Company. 3 The financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ("Ind-AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013. 4 Amounts for !he Quarter Ended March 31, 2026 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the respective financial years, which had been subjected only lo limited review • 5 Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/ year. For and on behalf of the Board of Directors of Place: ew Delhi Date: August 13, 2026 Dr. Rajesh Jain Chairman & Managing Director Panacea Biotec Limited Regd. Office: Ambala-Chandigarh Highway, Lalru- 140501, Punjab CIN: L33l 17PB1984PLC022350-Ph. No. 91-11-41679000, Fax: 91-11-41679070, Website: https://www.panacea-biolec.com, E-mail: Corporate@panaceabiotec.com "' Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter ended June 30, 2026 Panacea Biotec l•H>t,v. t,1·,, ,, .111,pr,r! r,t 1,11 (f in Lakh except per share) S.No Particulars Standalone Consolidated Quarter ended Year ended Quarter ended Year ended June 30, March 31, June 30, March 31, June 30, March 31, June 30, March 31, 2026 2026 2025 2026 2026 2026 2025 2026 (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Refer note 6) (Refer note 6) I Income: a) Revenue from operations 13,471 11,112 11,225 41,349 19,957 16,675 16,670 63,977 b) Other income 606 560 495 1,800 424 255 567 1.690 Total Income 14,077 11,672 11,720 43,149 20,381 16,930 17,237 65,667 11 Expenditure: a) Cost of raw and packing materials consumed 5,379 5,879 6,094 21,949 7,417 8,078 7,271 29,024 b) Purchase of traded goods 20 I 114 401 77 267 201 897 c) Changes in inventories of finished goods, traded goods and work-in-progress 2,401 (299) 6 (1,242) 2,677 (706) 250 (1,873) d) Employee benefits expense 2,283 2,276 2,537 10,033 4,416 4,682 4,572 18,078 e) Finance cost 689 633 600 2,530 118 120 86 605 f) Depreciation and amortisation expense 447 418 477 1,875 790 788 839 3,3 [Showing first 8,000 characters — download PDF for full document]